Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deletion of 17p in cancers: Guilt by (p53) association

18 Feb 2025

Abstract excerpt

Monoallelic deletion of the short arm of chromosome 17 (del17p) is a recurrent abnormality in cancers with poor outcomes. Best studied in relation to haematological malignancies, associated functional outcomes are attributed mainly to loss and/or dysfunction of TP53, which is located at 17p13.1, but the wider impact of deletion of other genes located on 17p is poorly understood. 17p is one of the most gene-dense...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39966556
DOI: 10.1038/s41388-025-03300-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deletion of 17p in cancers: Guilt by (p53) associationPMID 39966556Read ↗

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.Semantic proximity Read ↗

Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.Semantic proximity Read ↗

Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.Semantic proximity Read ↗

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in<i><scp>TP</scp>53</i>Semantic proximity Read ↗

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.Semantic proximity Read ↗

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.Semantic proximity Read ↗

Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer.Semantic proximity Read ↗

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Semantic proximity Read ↗

Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.